Jill Corre, PharmD, PhD, The Cancer University Institute of Toulouse Oncopole (IUCT), Toulouse, France, shares some insights into the importance of accurately identifying and risk stratifying high-risk myeloma patients. Dr Corre also discusses updated risk stratification systems and the role of cytogenetics. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.